ASTRAZENECA AB (20240269135). METHODS OF TREATING BREAST CANCER simplified abstract
Contents
METHODS OF TREATING BREAST CANCER
Organization Name
Inventor(s)
ANITRA Fielding of WILMINGTON DE (US)
METHODS OF TREATING BREAST CANCER - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240269135 titled 'METHODS OF TREATING BREAST CANCER
The patent application relates to methods for treating subjects with germline mutated BRCA1 and/or BRCA2 breast cancer who have previously undergone local treatment and neoadjuvant or adjuvant chemotherapy.
- The innovation involves adjuvant treatment for subjects with germline mutated BRCA1 and/or BRCA2 breast cancer after prior local treatment and chemotherapy.
- The method aims to improve outcomes for patients with this specific type of breast cancer.
- By targeting subjects with germline mutations in BRCA1 and/or BRCA2, the treatment is tailored to their genetic profile.
- The approach considers the unique needs of patients who have already received standard treatments for breast cancer.
- The innovation may lead to more effective and personalized care for individuals with germline mutated BRCA1 and/or BRCA2 breast cancer.
Potential Applications: - Oncology clinics - Research institutions studying breast cancer genetics - Pharmaceutical companies developing targeted therapies
Problems Solved: - Addressing the specific needs of patients with germline mutated BRCA1 and/or BRCA2 breast cancer - Enhancing treatment outcomes for individuals who have already undergone standard therapies
Benefits: - Personalized treatment approach based on genetic mutations - Improved outcomes for patients with germline mutated BRCA1 and/or BRCA2 breast cancer - Potential for more targeted and effective therapies in the future
Commercial Applications: Title: "Innovative Adjuvant Treatment for Germline Mutated BRCA1 and/or BRCA2 Breast Cancer" This technology could have significant commercial applications in the field of oncology, particularly in the development of personalized treatments for individuals with specific genetic mutations.
Questions about the technology: 1. How does this adjuvant treatment differ from standard therapies for breast cancer? - The treatment is tailored to individuals with germline mutated BRCA1 and/or BRCA2 breast cancer, offering a more personalized approach based on genetic profiles. 2. What are the potential long-term benefits of this targeted adjuvant treatment? - The treatment may lead to improved outcomes and survival rates for patients with germline mutated BRCA1 and/or BRCA2 breast cancer.
Original Abstract Submitted
this disclosure relates to methods for the adjuvant treatment of a subject having germline mutated brca1 and/or brca2 breast cancer, wherein the subject has previously received local treatment for the breast cancer. and neoadjuvant or adjuvant chemotherapy.
